Press Release
ZetrOZ Systems to Showcase sam(R) Wearable Ultrasound Unit for Pro Football Trainers
During the PFATS meeting at the NFL Medical Summit, the inventors of sustained acoustic medicine will demonstrate the technology and present research showing its effectiveness in accelerating soft tissue healing. Read More
Press Release
NLM Photonics to Demonstrate Industry-First Commercial Silicon-Organic Hybrid Modulator on a Multi-Channel PIC at OFC 50
Breakthrough photonic integrated circuit uses hybrid organic electro-optic technology to achieve best-in-class performance for next-generation data center applications. Read More
Press Release
GameSquare Accelerates Growth of Gaming and Esports Experiences Business and Divests Remaining Stake of FaZe Media
GameSquare expands strategic focus by bringing top gaming related events to the U.S. and adds new $2 million credit facility from Jones Family to support rapidly growing experiences business GameSquare divests remaining 25.5% stake in FaZe Media to Gigamoon Media and FaZe's founders as part of ongoing strategy to streamline operations, further improve balance sheet and pursue profitability GameSquare continues to own 100% of profitable FaZe Esports, one of the world's top-performing and highest winning esports organizations GameSquare to announce Q4 2024 earnings and provide profit focused financial expectations for 2025 on April 16, 2025 Read More
Press Release
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway -Company leveraging existing human pharmacokinetic data with TH104 -Advancing CMC plan to meet requirements of a New Drug Application Read More
Press Release
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast Read More
Press Release
Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter & Year-End 2024 Results
Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024 Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26 Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially Stockholders' Equity Was $7.1 Million at Year End Pending Acquisitions Remain on Track; TRNR Expects More than $50M in 2025 Pro Forma Revenue Read More
Press Release
Idaho Strategic Reports Record Operating and Financial Performance for 2024
Annual Revenue Increased 88.66%, While Annual Net Income Increased 663.27% Ended 2024 With Cash and Investments in US Treasury Notes Totaling $16,091,024 Achieved Nine Consecutive Quarters of GAAP Profitability Read More
Press Release
Azure Holding Group Corp ($AZRH) Forms Joint Venture with Mountain V, Begins First Phase of Natural Gas and Oil Drilling Program
Appalachian Mountain Energy, the joint venture, will drill new wells and rework existing wells currently owned and operated by Mountain V Oil & Gas across all 300,000 surface and mineral acres across the Appalachian Basin and Permian Basin that are currently held by production by Mountain V Oil & Gas. Read More
Press Release
DEA Forces Marijuana Pharma Drug Industry Offshore: A Symbol of DEA Systemic Obstruction Against Trump Administration Directives
"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation." DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer. Read More
Press Release
ALT5 Sigma Reports Strong Q4 and Full-Year 2024 Results, Achieves Milestones with Record Revenue, 1,000+ Customers, and Strategic Leadership Appointments
ALT5 Achieves Record-Breaking Q4 with $5.4 Million in Revenue Customer Base Surpasses 1,000 Accounts, a Historic Milestone Strong Annual Gross Margin of 50.2% and Impressive 18.2% Adjusted EBITDA¹ for Fintech Significant Working Capital Improvement of $4.5 Million Over Q3 Ron Pitters Appointed as New Chief Operating Officer Read More
Press Release
Grand Slam Track Announces Rekortan as Official Track Partner for 2025 Inaugural Grand Slam Track Season; Track Resurfacing Project Complete at National Stadium in Jamaica
Rekortan will support with track quality and maintenance, warm-up areas, equipment provision, and other sports surfaces for Slams in Kingston, Miami, Philadelphia, and Los Angeles Read More
Press Release
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets Read More
Press Release